<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304238</url>
  </required_header>
  <id_info>
    <org_study_id>108745</org_study_id>
    <nct_id>NCT01304238</nct_id>
  </id_info>
  <brief_title>Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II</brief_title>
  <official_title>Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this retrospective registry is to collect data about patients with acute HIT
      II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid,
      Argatroban or Fondaparinux. It is a main objective of this registry to mirror the daily
      routine in this indication in Germany.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II</measure>
    <time_frame>19 January 2005 to 25 October 2009</time_frame>
    <description>Thrombosis is a clotting in a blood vessel. Pulmonary embolism is a clot, usually from the deep veins of the legs, carried away with the venous bloodstream into the lungs, where it may block pulmonary vessels. Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Diagnosed With Bleeding After the Occurrence of HIT II</measure>
    <time_frame>19 January 2005 to 25 October 2009</time_frame>
    <description>Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Bleeding was documented in the participant files.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Fatal Complications After the Occurrence of HIT II</measure>
    <time_frame>19 January 2005 to 25 October 2009</time_frame>
    <description>Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). A fatal complication is defined as a complication resulting in death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Underwent Amputation After the Occurrence of HIT II</measure>
    <time_frame>19 January 2005 to 25 October 2009</time_frame>
    <description>Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Diagnosed With Thrombocytopenia (Recurrent of Persistent) After the Occurrence of HIT II</measure>
    <time_frame>19 January 2005 to 25 October 2009</time_frame>
    <description>Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Thrombocytopenia after HIT-II was documented in the participant files.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Skin Changes (Erythema and Necrosis) After the Occurrence of HIT II</measure>
    <time_frame>19 January 2005 to 25 October 2009</time_frame>
    <description>Participants' medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Erythema is a redness of the skin caused by hyperemia. Necrosis is the premature death of cells or tissues.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">195</enrollment>
  <condition>Acute HIT II (Heparin-induced Thrombocytopenia Type II)</condition>
  <arm_group>
    <arm_group_label>lepirudin</arm_group_label>
    <description>lepirudin treated subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>danaparoid</arm_group_label>
    <description>danaparoid treated subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>argatroban</arm_group_label>
    <description>argatroban treated subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fondaparinux</arm_group_label>
    <description>fondaparinux treated subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lepirudin</intervention_name>
    <description>lepirudin</description>
    <arm_group_label>lepirudin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danaparoid</intervention_name>
    <description>danaparoid</description>
    <arm_group_label>danaparoid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>argatroban</intervention_name>
    <description>argatroban</description>
    <arm_group_label>argatroban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fondaparinux</intervention_name>
    <description>fondaparinux</description>
    <arm_group_label>fondaparinux</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients with HIT
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute HIT II (Heparin-induced Thrombocytopenia type II), 4T-Score

          -  Treatment of HIT with Lepirudin, Danaparoid, Argatroban or Fondaparinux

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <results_first_submitted>January 27, 2011</results_first_submitted>
  <results_first_submitted_qc>January 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2011</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retrospective evaluation of patients with acute Heparin-induced Thrombocytopenia type II treated with Fondaparinux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Argatroban</mesh_term>
    <mesh_term>Lepirudin</mesh_term>
    <mesh_term>Danaproid</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Dermatan Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Argatroban</title>
          <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
        </group>
        <group group_id="P2">
          <title>Lepirudin</title>
          <description>Participants treated with lepirudin after HIT II</description>
        </group>
        <group group_id="P3">
          <title>Danaparoid</title>
          <description>Participants treated with danaparoid after HIT II</description>
        </group>
        <group group_id="P4">
          <title>Fondaparinux</title>
          <description>Participants treated with fondaparinux after HIT II</description>
        </group>
        <group group_id="P5">
          <title>Argatroban/Fondaparinux</title>
          <description>Participants treated with argatroban and fondaparinux after HIT II</description>
        </group>
        <group group_id="P6">
          <title>Danaparoid/Argatroban</title>
          <description>Participants treated with danaparoid and argatroban after HIT II</description>
        </group>
        <group group_id="P7">
          <title>Danaparoid/Fondaparinux</title>
          <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
        </group>
        <group group_id="P8">
          <title>Danaparoid/Lepirudin</title>
          <description>Participants treated with danaparoid and lepirudin after HIT II</description>
        </group>
        <group group_id="P9">
          <title>Danaparoid/Fondaparinux/Lepirudin</title>
          <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
        </group>
        <group group_id="P10">
          <title>Argatroban/Danaparoid/Fondaparinux</title>
          <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="78"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="78"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Argatroban</title>
          <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
        </group>
        <group group_id="B2">
          <title>Lepirudin</title>
          <description>Participants treated with lepirudin after HIT II</description>
        </group>
        <group group_id="B3">
          <title>Danaparoid</title>
          <description>Participants treated with danaparoid after HIT II</description>
        </group>
        <group group_id="B4">
          <title>Fondaparinux</title>
          <description>Participants treated with fondaparinux after HIT II</description>
        </group>
        <group group_id="B5">
          <title>Argatroban/Fondaparinux</title>
          <description>Participants treated with argatroban and fondaparinux after HIT II</description>
        </group>
        <group group_id="B6">
          <title>Danaparoid/Argatroban</title>
          <description>Participants treated with danaparoid and argatroban after HIT II</description>
        </group>
        <group group_id="B7">
          <title>Danaparoid/Fondaparinux</title>
          <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
        </group>
        <group group_id="B8">
          <title>Danaparoid/Lepirudin</title>
          <description>Participants treated with danaparoid and lepirudin after HIT II</description>
        </group>
        <group group_id="B9">
          <title>Danaparoid/Fondaparinux/Lepirudin</title>
          <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
        </group>
        <group group_id="B10">
          <title>Argatroban/Danaparoid/Fondaparinux</title>
          <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="78"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="11"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="1"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="195"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.4" spread="12.3"/>
                    <measurement group_id="B2" value="61.8" spread="13.7"/>
                    <measurement group_id="B3" value="67.8" spread="13.0"/>
                    <measurement group_id="B4" value="71.7" spread="11.4"/>
                    <measurement group_id="B5" value="71.5" spread="12.1"/>
                    <measurement group_id="B6" value="60.0" spread="14.0"/>
                    <measurement group_id="B7" value="71.0" spread="8.6"/>
                    <measurement group_id="B8" value="55.3" spread="16.0"/>
                    <measurement group_id="B9" value="56.0" spread="0.0"/>
                    <measurement group_id="B10" value="63.7" spread="7.5"/>
                    <measurement group_id="B11" value="68.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>Gender information is missing in one participant in the lepirudin arm.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants receiving the indicated heparin treatment prior to HIT II</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Only unfractionated heparin (UFH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Only low molecular weight heparin (LMWH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UFH and LMWH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants receiving the indicated AT before HIT II with regard to rationale</title>
          <description>Multiple responses are possible. AT, anticoagulant treatment. “Rationale” refers to the initial reason for giving antithrombotics, e.g., for prophylaxis or for therapy of thrombosis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prophylactic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapeutic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants receving the indicated AT before HIT II (specified) with regard to rationale</title>
          <description>Multiple responses are possible. AT, anticoagulant treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prophylaxis (no further specification)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylaxis: Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylaxis: Internal Medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylaxis: Neurology/Neurosurgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indication for thromboembolic therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with the indicated thromboembolic therapy (specified)</title>
          <description>Multiple responses are possible.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Deep vein thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral artery occlusive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute coronary syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alternative anticoagulation in atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alternative anticoagulation in cardiac valve</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II</title>
        <description>Thrombosis is a clotting in a blood vessel. Pulmonary embolism is a clot, usually from the deep veins of the legs, carried away with the venous bloodstream into the lungs, where it may block pulmonary vessels. Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs).</description>
        <time_frame>19 January 2005 to 25 October 2009</time_frame>
        <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
        <group_list>
          <group group_id="O1">
            <title>Argatroban</title>
            <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
          </group>
          <group group_id="O2">
            <title>Lepirudin</title>
            <description>Participants treated with lepirudin after HIT II</description>
          </group>
          <group group_id="O3">
            <title>Danaparoid</title>
            <description>Participants treated with danaparoid after HIT II</description>
          </group>
          <group group_id="O4">
            <title>Fondaparinux</title>
            <description>Participants treated with fondaparinux after HIT II</description>
          </group>
          <group group_id="O5">
            <title>Argatroban/Fondaparinux</title>
            <description>Participants treated with argatroban and fondaparinux after HIT II</description>
          </group>
          <group group_id="O6">
            <title>Danaparoid/Argatroban</title>
            <description>Participants treated with danaparoid and argatroban after HIT II</description>
          </group>
          <group group_id="O7">
            <title>Danaparoid/Fondaparinux</title>
            <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
          </group>
          <group group_id="O8">
            <title>Danaparoid/Lepirudin</title>
            <description>Participants treated with danaparoid and lepirudin after HIT II</description>
          </group>
          <group group_id="O9">
            <title>Danaparoid/Fondaparinux/Lepirudin</title>
            <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
          </group>
          <group group_id="O10">
            <title>Argatroban/Danaparoid/Fondaparinux</title>
            <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II</title>
          <description>Thrombosis is a clotting in a blood vessel. Pulmonary embolism is a clot, usually from the deep veins of the legs, carried away with the venous bloodstream into the lungs, where it may block pulmonary vessels. Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs).</description>
          <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No thrombosis or pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis and pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Diagnosed With Bleeding After the Occurrence of HIT II</title>
        <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Bleeding was documented in the participant files.</description>
        <time_frame>19 January 2005 to 25 October 2009</time_frame>
        <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
        <group_list>
          <group group_id="O1">
            <title>Argatroban</title>
            <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
          </group>
          <group group_id="O2">
            <title>Lepirudin</title>
            <description>Participants treated with lepirudin after HIT II</description>
          </group>
          <group group_id="O3">
            <title>Danaparoid</title>
            <description>Participants treated with danaparoid after HIT II</description>
          </group>
          <group group_id="O4">
            <title>Fondaparinux</title>
            <description>Participants treated with fondaparinux after HIT II</description>
          </group>
          <group group_id="O5">
            <title>Argatroban/Fondaparinux</title>
            <description>Participants treated with argatroban and fondaparinux after HIT II</description>
          </group>
          <group group_id="O6">
            <title>Danaparoid/Argatroban</title>
            <description>Participants treated with danaparoid and argatroban after HIT II</description>
          </group>
          <group group_id="O7">
            <title>Danaparoid/Fondaparinux</title>
            <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
          </group>
          <group group_id="O8">
            <title>Danaparoid/Lepirudin</title>
            <description>Participants treated with danaparoid and lepirudin after HIT II</description>
          </group>
          <group group_id="O9">
            <title>Danaparoid/Fondaparinux/Lepirudin</title>
            <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
          </group>
          <group group_id="O10">
            <title>Argatroban/Danaparoid/Fondaparinux</title>
            <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Diagnosed With Bleeding After the Occurrence of HIT II</title>
          <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Bleeding was documented in the participant files.</description>
          <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Fatal Complications After the Occurrence of HIT II</title>
        <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). A fatal complication is defined as a complication resulting in death.</description>
        <time_frame>19 January 2005 to 25 October 2009</time_frame>
        <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
        <group_list>
          <group group_id="O1">
            <title>Argatroban</title>
            <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
          </group>
          <group group_id="O2">
            <title>Lepirudin</title>
            <description>Participants treated with lepirudin after HIT II</description>
          </group>
          <group group_id="O3">
            <title>Danaparoid</title>
            <description>Participants treated with danaparoid after HIT II</description>
          </group>
          <group group_id="O4">
            <title>Fondaparinux</title>
            <description>Participants treated with fondaparinux after HIT II</description>
          </group>
          <group group_id="O5">
            <title>Argatroban/Fondaparinux</title>
            <description>Participants treated with argatroban and fondaparinux after HIT II</description>
          </group>
          <group group_id="O6">
            <title>Danaparoid/Argatroban</title>
            <description>Participants treated with danaparoid and argatroban after HIT II</description>
          </group>
          <group group_id="O7">
            <title>Danaparoid/Fondaparinux</title>
            <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
          </group>
          <group group_id="O8">
            <title>Danaparoid/Lepirudin</title>
            <description>Participants treated with danaparoid and lepirudin after HIT II</description>
          </group>
          <group group_id="O9">
            <title>Danaparoid/Fondaparinux/Lepirudin</title>
            <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
          </group>
          <group group_id="O10">
            <title>Argatroban/Danaparoid/Fondaparinux</title>
            <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Complications After the Occurrence of HIT II</title>
          <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). A fatal complication is defined as a complication resulting in death.</description>
          <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No fatal complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Underwent Amputation After the Occurrence of HIT II</title>
        <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs).</description>
        <time_frame>19 January 2005 to 25 October 2009</time_frame>
        <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
        <group_list>
          <group group_id="O1">
            <title>Argatroban</title>
            <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
          </group>
          <group group_id="O2">
            <title>Lepirudin</title>
            <description>Participants treated with lepirudin after HIT II</description>
          </group>
          <group group_id="O3">
            <title>Danaparoid</title>
            <description>Participants treated with danaparoid after HIT II</description>
          </group>
          <group group_id="O4">
            <title>Fondaparinux</title>
            <description>Participants treated with fondaparinux after HIT II</description>
          </group>
          <group group_id="O5">
            <title>Argatroban/Fondaparinux</title>
            <description>Participants treated with argatroban and fondaparinux after HIT II</description>
          </group>
          <group group_id="O6">
            <title>Danaparoid/Argatroban</title>
            <description>Participants treated with danaparoid and argatroban after HIT II</description>
          </group>
          <group group_id="O7">
            <title>Danaparoid/Fondaparinux</title>
            <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
          </group>
          <group group_id="O8">
            <title>Danaparoid/Lepirudin</title>
            <description>Participants treated with danaparoid and lepirudin after HIT II</description>
          </group>
          <group group_id="O9">
            <title>Danaparoid/Fondaparinux/Lepirudin</title>
            <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
          </group>
          <group group_id="O10">
            <title>Argatroban/Danaparoid/Fondaparinux</title>
            <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Underwent Amputation After the Occurrence of HIT II</title>
          <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs).</description>
          <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Diagnosed With Thrombocytopenia (Recurrent of Persistent) After the Occurrence of HIT II</title>
        <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Thrombocytopenia after HIT-II was documented in the participant files.</description>
        <time_frame>19 January 2005 to 25 October 2009</time_frame>
        <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
        <group_list>
          <group group_id="O1">
            <title>Argatroban</title>
            <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
          </group>
          <group group_id="O2">
            <title>Lepirudin</title>
            <description>Participants treated with lepirudin after HIT II</description>
          </group>
          <group group_id="O3">
            <title>Danaparoid</title>
            <description>Participants treated with danaparoid after HIT II</description>
          </group>
          <group group_id="O4">
            <title>Fondaparinux</title>
            <description>Participants treated with fondaparinux after HIT II</description>
          </group>
          <group group_id="O5">
            <title>Argatroban/Fondaparinux</title>
            <description>Participants treated with argatroban and fondaparinux after HIT II</description>
          </group>
          <group group_id="O6">
            <title>Danaparoid/Argatroban</title>
            <description>Participants treated with danaparoid and argatroban after HIT II</description>
          </group>
          <group group_id="O7">
            <title>Danaparoid/Fondaparinux</title>
            <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
          </group>
          <group group_id="O8">
            <title>Danaparoid/Lepirudin</title>
            <description>Participants treated with danaparoid and lepirudin after HIT II</description>
          </group>
          <group group_id="O9">
            <title>Danaparoid/Fondaparinux/Lepirudin</title>
            <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
          </group>
          <group group_id="O10">
            <title>Argatroban/Danaparoid/Fondaparinux</title>
            <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Diagnosed With Thrombocytopenia (Recurrent of Persistent) After the Occurrence of HIT II</title>
          <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Thrombocytopenia after HIT-II was documented in the participant files.</description>
          <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recurrent thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Skin Changes (Erythema and Necrosis) After the Occurrence of HIT II</title>
        <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Erythema is a redness of the skin caused by hyperemia. Necrosis is the premature death of cells or tissues.</description>
        <time_frame>19 January 2005 to 25 October 2009</time_frame>
        <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
        <group_list>
          <group group_id="O1">
            <title>Argatroban</title>
            <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
          </group>
          <group group_id="O2">
            <title>Lepirudin</title>
            <description>Participants treated with lepirudin after HIT II</description>
          </group>
          <group group_id="O3">
            <title>Danaparoid</title>
            <description>Participants treated with danaparoid after HIT II</description>
          </group>
          <group group_id="O4">
            <title>Fondaparinux</title>
            <description>Participants treated with fondaparinux after HIT II</description>
          </group>
          <group group_id="O5">
            <title>Argatroban/Fondaparinux</title>
            <description>Participants treated with argatroban and fondaparinux after HIT II</description>
          </group>
          <group group_id="O6">
            <title>Danaparoid/Argatroban</title>
            <description>Participants treated with danaparoid and argatroban after HIT II</description>
          </group>
          <group group_id="O7">
            <title>Danaparoid/Fondaparinux</title>
            <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
          </group>
          <group group_id="O8">
            <title>Danaparoid/Lepirudin</title>
            <description>Participants treated with danaparoid and lepirudin after HIT II</description>
          </group>
          <group group_id="O9">
            <title>Danaparoid/Fondaparinux/Lepirudin</title>
            <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
          </group>
          <group group_id="O10">
            <title>Argatroban/Danaparoid/Fondaparinux</title>
            <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Skin Changes (Erythema and Necrosis) After the Occurrence of HIT II</title>
          <description>Participants’ medical records were used to abstract data that were collected on standardized hard copy Case Report Forms (CRFs). Erythema is a redness of the skin caused by hyperemia. Necrosis is the premature death of cells or tissues.</description>
          <population>All documented participants diagnosed with suspected acute HIT II and a 4T Score of ≥4 who had received at least one dose of argatroban, lepirudin, danaparoid, or fondaparinux. The 4T score (range: 0-8) was developed to predict the probability of HIT.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No skin changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is a retrospective study of pre-existing medical record data; thus, no assessments of serious or non-serious adverse events are possible.</desc>
      <group_list>
        <group group_id="E1">
          <title>Argatroban</title>
          <description>Participants treated with argatroban after Heparin-induced thrombocytopenia Type-II (HIT II)</description>
        </group>
        <group group_id="E2">
          <title>Lepirudin</title>
          <description>Participants treated with lepirudin after HIT II</description>
        </group>
        <group group_id="E3">
          <title>Danaparoid</title>
          <description>Participants treated with danaparoid after HIT II</description>
        </group>
        <group group_id="E4">
          <title>Fondaparinux</title>
          <description>Participants treated with fondaparinux after HIT II</description>
        </group>
        <group group_id="E5">
          <title>Argatroban/Fondaparinux</title>
          <description>Participants treated with argatroban and fondaparinux after HIT II</description>
        </group>
        <group group_id="E6">
          <title>Danaparoid/Argatroban</title>
          <description>Participants treated with danaparoid and argatroban after HIT II</description>
        </group>
        <group group_id="E7">
          <title>Danaparoid/Fondaparinux</title>
          <description>Participants treated with danaparoid and fondaparinux after HIT II</description>
        </group>
        <group group_id="E8">
          <title>Danaparoid/Lepirudin</title>
          <description>Participants treated with danaparoid and lepirudin after HIT II</description>
        </group>
        <group group_id="E9">
          <title>Danaparoid/Fondaparinux/Lepirudin</title>
          <description>Participants treated with danaparoid, fondaparinux, and lepirudin after HIT II</description>
        </group>
        <group group_id="E10">
          <title>Argatroban/Danaparoid/Fondaparinux</title>
          <description>Participants treated with argatroban, danaparoid, and fondaparinux after HIT II</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the retrospective nature of the data collection in this study, it is impossible to be precise about dose and frequency of dosing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Cente</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

